August 5, 2020
First MR-Linac in Taiwan Provides Patients Access to MR-Guided Radiation Therapy
CLEVELAND, Aug. 5, 2020 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that Kaohsiung Medical University Chung-Ho Memorial
Hospital (KMUH) in Kaohsiung City, Taiwan has begun patient treatments with the MRIdian® MR-Guided Radiation Therapy System, a cutting-edge
device that delivers personalized cancer care by combining the latest innovations in precision radiation delivery with ground-breaking
MR-guidance. The first two patients treated at KMUH on MRIdian were provided care for prostate cancer and tumor lesions in the left lung. Both
treatments took advantage of MRIdian’s automated beam-gating technology, protecting surrounding organs at risk.
The MRIdian system utilizes on-table soft-tissue imaging to allow clinicians to visualize cancer tumors with diagnostic-quality anatomical detail that is
unavailable with conventional image-guided radiation therapy (IGRT) technologies. The system combines real-time imaging with the ability to adapt
the treatment as needed, based on daily changes in tumor shape, size or position, for greater accuracy. The device also provides automated
beam-gating, which stops the delivery of radiation when the tumor moves outside of the target area or when healthy tissue moves into the target
range. Together, these features help protect healthy tissue and critical organs, while precisely targeting the tumor with a high dose of radiation.
MRIdian provides a compelling level of personalization, precision and accuracy.
“I am moved by the professionals from all over the world who gathered at KMUH to complete the installation of our MRIdian system during the
COVID-19 pandemic,” said Dr. Chun-Ming Huang, who is a physician in the radiation oncology department at the hospital. “How exciting it is to finally
see everything that could not be seen in the past and to treat our patients with online, real-time adaptive radiotherapy.”
“We’re pleased to have KUMH join the growing list of hospitals to offer the benefits of MRIdian to their patients,” said Paul Ziegler, Senior Vice
President of Sales and Marketing at ViewRay. “As hospitals explore ways to deliver effective cancer treatments while also minimizing patient visits
during these challenging times, MRIdian’s ability to deliver radiation therapy in fewer treatment sessions becomes even more valuable.”
The MRIdian at Chung-Ho Memorial Hospital is the first in Taiwan and the fifth in Asia. Currently, 38 MRIdian systems are installed at hospitals around
the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the
subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. The number of patients treated on MRIdian is
nearly 10,000. For a list of treatment centers, please visit https://viewray.com/mridian-locator.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary
high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation
oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including
beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.